Back

Prescription of lipid-lowering therapy, LDLc control, and risk of MACE in patients after ST-elevation myocardial infarction in Mexico

9 March 2024 (09:40 - 10:25)
Organised by: Logo
Congress Presentation Part of: Risk factors, prevention, and pharmacotherapy Secondary Prevention ACVC Premium Access ESC Acute CardioVascular Care 2024 Association for Acute CardioVascular Care (ACVC)

About the speaker

Photo
Miss Sarai Hernandez Pastrana

National Institute of Cardiology Ignacio Chavez, Mexico City (Mexico)

6 More presentations in this session

Presentation thumbnail
Cardiac rehabilitation makes a difference: lipid control targets and prognosis.
Mrs M. Lucas Garcia (Sevilla, Spain, ES)
Abstract Slides
Presentation thumbnail
The lipid profile of the young patient with ischemic heart disease. Do these patients meet the goals?
Doctor M. Pelaz Sanchez (Seville, ES)
Abstract Slides
Presentation thumbnail
Risk factors for intensive care admission in pediatric patients with COVID-19 - results of the German na-tionwide inpatient sample
Doctor K. Keller (Mainz, DE)
Abstract Slides
Presentation thumbnail
Combining rivaroxaban with aspirin for peripheral artery disease: an in-depth systematic review and meta-analysis
Doctor B. David (Global City, PH)
Abstract Slides
Presentation thumbnail
P2Y12 monotherapy versus standard dual antiplatelet therapy after percutaneous coronary intervention: a systematic review and meta-analysis
Doctor B. Buot (Quezon City, PH)
Abstract Slides

Access the full session

Session thumbnail
Risk factors, prevention, and pharmacotherapy

The Event

Event poster

ESC Acute CardioVascular Care 2024

9 March 2024 09:40 CET
You may be interested in
thumbnail
Congress Presentation
Secondary prevention after one-year of a cardiovascular rehabilitation program: a single-centre analysis
thumbnail
Congress Presentation
Secondary prevention in young patients after acute ST segment elevation myocardial infarction: missing the goals and suffering the penalties
thumbnail
Webinar
Personalised secondary prevention post-ACS: the role of biomarkers

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources